Patent and Intelectual Property Rights

Patent protection secured in key markets

The company’s intellectual property portfolio consists of several approved patents and patent applications based on unique chemical compounds in the form of aptamer-based drug candidates and their applications. The drug candidates are protected by the strongest form of patent protection in the pharmaceutical industry, entailing that the unique RNA aptamers hold product patent protection.

For recently acquired patentable technology, Aptahem strategically plans to apply for patents in countries that are expected to become key markets for the company in the future. Currently, the following markets are being considered: Europe, the US, Canada and certain important markets in Asia and the rest of the world. The company intends to apply for additional patents in the event that the Board considers that the company should strengthen the intellectual property portfolio further.

Patent family 1

Region Application number Application date Expiration date Status
Europe 09708523.7 2009-02-05 2029-02-05 Approved
USA 12/866413 2009-02-05 2029-02-05 Approved
Canada 2714121 2009-02-05 2029-02-05 Approved
China 20098011646.4 2009-02-05 2029-02-05 Approved
India 6250/DELNP/2010 2009-02-05 2029-02-05 Ongoing

Patent family 2

Region Application number Application date Expiration date Status
PCT application* WO/2019/068766 2017-10-03 2037-10-03 Ongoing

* Patent Cooperation Treaty, PCT, is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent Offices in what is called the “national phase”.
Source: World Intellectual Property Organization (WIPO,